Though noncancerous, the tumors can decrease quality of life.
The U.S. Food and Drug Administration (FDA) recently approved Ogsiveo (nirogacestat) tablets as the first-ever treatment for desmoid tumors—a rare form of noncancerous soft tissue sarcomas. Though non-cancerous, desmoid tumors can be locally aggressive, causing pain, mobility issues, and a decreased quality of life as they invade surrounding structures and organs.
While surgery has been the primary treatment, the high risk of recurrence or other health complications has prompted increased evaluation of systemic therapies.
“Desmoid tumors are rare tumors that can lead to severe pain and disability,” said FDA’s Oncology Center of Excellence Director Richard Pazdur, who also serves as acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research. “Today’s approval will offer the first approved treatment option for patients beyond surgery and radiation.”
As the Lord Leads, Pray with Us…
- For discernment for Director Pazdur as he oversees that oncology centers of the FDA.
- For Commissioner Robert Califf to be led by God as he heads the Food and Drug Administration.
- For healing and wholeness for those who are suffering from desmoid tumors.
Sources: Food and Drug Administration
